Eliem Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 28, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 28, 2024

CLYM$11.01+7.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

	As of December 31,
	2023	2022
Assets
Current assets:
Cash and cash equivalents	$93,112	$43,585
Short-term marketable securities	13,686	79,981
Prepaid expenses and other current assets	3,457	10,827
Total current assets	$110,255	$134,393
Operating lease right-of-use assets	199	471
Other long-term assets	15	128
Total assets	$110,469	$134,992
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$66	$750
Accrued expenses and other current liabilities	2,433	5,047
Operating lease liabilities	334	300
Total current liabilities	$2,833	$6,097
Other long-term liabilities	22	—
Operating lease liabilities, net of current portion	15	180
Total liabilities	$2,870	$6,277
Commitments and contingencies (Note 5)
Stockholders’ equity
Common stock, $0.0001 par value per share, 250,000,000 shares authorized; 27,699,446 and 26,567,681 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	3	3
Additional paid-in capital	263,577	249,930
Accumulated other comprehensive loss	(2)	(358)
Accumulated deficit	(155,979)	(120,860)
Total stockholders’ equity	$107,599	$128,715
Total liabilities and stockholders’ equity	$110,469	$134,992

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.